Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis
China176 participantsStarted 2023-06-15
Plain-language summary
This is a multicenter randomized, placebo-controlled trial of Vitamin D supplementation in patients on peritoneal dialysis to determine whether oral administration of vitamin D3 after curing an episode of peritonitis could reduce the risk of subsequent peritoneal dialysis-related peritonitis.
Who can participate
Age range19 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Medically stable and receiving peritoneal dialysis for \> 1 month
* Older than 18 years old
* Serum 25(OH)D \< 30ng/ml
* Adequate dialysis on evaluation with weekly Kt/V ā„ 1.5, or (revised time: 2023-7-11) without clinical uremic symptoms
Exclusion Criteria:
* Receive Vitamin D2/D3 during the previous 1 month (revised time: 2023-7-11) ;
* History of allergic reaction to Cholecalciferol;
* Current or past malignant disease, active hepatitis or hepatic failure, active autoimmune disease, severe digestive malabsorption or an eating disorder, HIV/AIDS;
* Acute systemic infection, cardiovascular disease, surgery, or trauma in the last month;
* A high probability of receiving a kidney transplant or transferring to hemodialysis or drop-out due to socioeconomic causes within 6 months;
* History of kidney transplant;
* Hemodialysis combined with peritoneal dialysis currently;
* Pregnant or breastfeeding;
* Not suitable enrolled assessed by researchers, including patients who could not regular follow-up